24th Edition
Strategic Project & Portfolio Management for Pharma
Optimising tools and processes to drive PPM efficiency and steer high efficiency projects
ENTER YOUR DETAILS FOR THE CONFERENCE AGENDA
What are the anticipated trends and potential challenges within PPM for Pharma?
The adoption of artificial intelligence and machine learning to enhance project portfolio management represents a massive transformation of ways of working that is just starting. I have no doubt that AI will play a critical role in leveraging data from various scattered sources, such as clinical trials, market research, and customer feedback, to generate critical insights and predictions that can inform project selection and portfolio optimization. With the ever-growing focus on generative AI tests and implementation, come challenges, such as data quality, security, and ethics, as well as organizational readiness, culture, and change management.
What, for you, are the benefits of attending this Strategic PPM conference and what can attendees expect to learn from your presentation?
Attendees can take inspiration from the best practices and experiences of leading pharma and biotech companies and experts in the field of PPM. One of the greatest benefits is networking and an opportunity to follow up with the speakers on the points relevant to you – this helps advance our understanding of the latest trends, challenge the status quo, and learn from each other. Among other topics, I look forward to jointly reflecting on how to boost the adoption of generative AI technology in PPM and support our staff during this transformation.
How has technology reshaped the role and the processes within PPM?
Technology has revolutionized Project Portfolio Management (PPM), automating critical tasks such as project tracking and resource allocation, resulting in reduced manual efforts and improved efficiency. These advancements not only enhance quality but also free up time for PPM professionals, enabling a shift towards more strategic roles in collaboration with the business. Moreover, the emergence of generative AI introduces transformative potential within PPM. This technology could fundamentally alter PPM operations by, among other things, automating complex decision-making processes and better predicting project outcomes, resulting in an improvement in the overall probability of success for drug projects.
What are the core factors for a successful PPM and how to ensure you have the right capabilities?
Maintaining an open mind, challenging the status quo, and anticipating emerging trends are vital in effective Project Portfolio Management. This involves questioning assumptions, practices, and metrics for continuous improvement. The pivotal element of adaptability lies in skillfully balancing the initiation of new projects and the discontinuation of existing ones—employing both addition and subtraction strategies.
Ahead of the 24th Edition Strategic Project & Portfolio Management for Pharma conference we spoke with Maciej Szymaszek, Senior Director, Strategy Implementation & Business Transformation at Global Portfolio & Project Management at AstraZeneca, The United States. Maciej is an experienced Project Portfolio Leader and Strategist with a track record of delivering outstanding results across diverse cultural and organizational environments in pharmaceuticals, health care, IT and research.
17-19 January, 2024
Frankfurt, Germany
Maciej will be co-presenting a case study with Maurice Storey, Senior Director Portfolio Systems, Global Portfolio & Project Management at AstraZeneca, Sweden during day one of the 24th Edition Strategic Project and Portfolio Management for Pharma conference!
Case Study: Leveraging Generative AI in Project Portfolio Management Organisations
Generative AI is a game-changer for project portfolio management, holding the potential to fundamentally alter how we operate across all layers and functions of PPM organisations in the pharmaceutical industry.
By 2030, it is estimated that a staggering 80% of project management tasks will be automated.
This interactive session will focus on the initial real-world applications of Generative AI in a pharmaceutical project portfolio management organisation.
For registration pricing and multiple attendee discounts, please contact:
Ria Kiayia
All Rights Reserved. marcus evans ® 2023
Interested? Do you feel you will benefit?
An interview with Maciej Szymaszek, Senior Director, Strategy Implementation & Business Transformation at Global Portfolio & Project Management at AstraZeneca, The United States
